Manufacturing USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns BioSpaceAlmost half of the top 100 medicines vulnerable to supply disruptions in the U.S.ManufacturingRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. ManufacturingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Allogene stock sails after CAR T clears residual lymphoma in early data cutNext: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results Related Stories Manufacturing FDA Warning Letter Hits Sanofi’s Genzyme Ireland Site pharminent July 8, 2026 Manufacturing Tanabe pens deal to sell plants to Towa in post-buyout pivot pharminent July 8, 2026 Manufacturing FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing pharminent July 1, 2026
